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ABSTRACT
In Epstein-Barr virus-infected epithelial cancers, the alternatively spliced BamHI A rightward transcripts (BARTs) are the most
abundant viral polyadenylated RNA. The BART introns form the template for the production of 44 microRNAs (miRNAs), and
the spliced and polyadenylated exons form nuclear non-protein-coding RNAs. Analysis of host cell transcription by RNA-seq
during latency in AGS cells identified a large number of reproducibly changed genes. Genes that were downregulated were en-
riched for BART miRNA targets. Bioinformatics analysis predicted activation of the myc pathway and downregulation of XBP1
as likely mediators of the host transcriptional changes. Effects on XBP1 activity were not detected in these cells; however, myc
activation was confirmed through use of a myc-responsive luciferase reporter. To identify potential regulatory properties of the
spliced, polyadenylated BART RNAs, a full-length cDNA clone of one of the BART isoforms was obtained and expressed in the
Epstein-Barr virus (EBV)-negative AGS cells. The BART cDNA transcript remained primarily nuclear yet induced considerable
and consistent changes in cellular transcription, as profiled by RNA-seq. These transcriptional changes significantly overlapped
the transcriptional changes induced during latent EBV infection of these same cells, where the BARTs are exclusively nuclear and
do not encode proteins. These data suggest that the nuclear BART RNAs are functional long noncoding RNAs (lncRNAs). The
abundant expression of multiple forms of noncoding RNAs that contribute to growth regulation without expression of immuno-
genic proteins would be an important mechanism for viral oncogenesis in the presence of a functional immune system.
IMPORTANCE
Infection with Epstein-Barr virus (EBV) is nearly ubiquitous in the human population; however, it does contribute to the forma-
tion of multiple types of cancer. In immunocompromised patients, EBV causes multiple types of lymphomas by expressing viral
oncogenes that promote growth and survival of infected B lymphocytes. EBV-positive gastric carcinoma does not require im-
mune suppression, and the viral oncoproteins that are frequent targets for an immunological response are not expressed. This
study demonstrates using transcriptional analysis that the expression of various classes of viral non-protein-coding RNAs likely
contribute to the considerable changes in the host transcriptional profile in the AGS gastric cancer cell line. This is the first re-
port to show that the highly expressed polyadenylated BamHI A rightward transcripts (BART) viral transcript in gastric carci-
noma is in fact a functional viral long noncoding RNA. These studies provide new insight into how EBV can promote transfor-
mation in the absence of viral protein expression.
Latent infection with Epstein-Barr virus (EBV), a nearly ubiq-uitous human herpesvirus, is responsible for multiple malig-
nancies in the two types of cells that it infects: B lymphocytes and
epithelial cells (1). The mechanism by which EBV leads to trans-
formation depends on both the properties of the host cell and the
state of the host immune system. Infection of primary B cells with
EBV in vitro is sufficient for immortalization, which results from
the expression of a set of latent viral proteins that have oncogenic
properties (1). This type of latent protein expression, termed la-
tency III, is also observed in EBV-driven lymphomas that develop
in immunocompromised individuals. In EBV-associated lympho-
mas or carcinomas that develop in individuals with a healthy im-
mune system, a much more restricted pattern of viral protein ex-
pression is observed (2). However, these tumors are clonally
infected with EBV, suggesting that EBV infection is an early event
in the formation of the tumors (3). Consistent with these obser-
vations, EBV infection of an epithelial cell line in vitro is capable of
promoting growth in soft agar independent of any latent protein
expression (4).
EBV epithelial malignancies, nasopharyngeal and gastric car-
cinomas, exhibit a unique expression pattern that includes exten-
sive transcription from the BamHI A region of the viral genome
(5). The transcription from this region consists of a set of highly
expressed and alternatively spliced transcripts that are called the
BamHI A rightward transcripts (BARTs) (6). These transcripts
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contain multiple open reading frames (ORFs) dependent upon
splicing pattern (BARF0, A73, and RPMS1); however, proteins
have not been detected from the endogenous translation of these
ORFs (7, 8). A first clue to the actual function of these transcripts
came from the discovery that the introns of these transcripts con-
tained 22 microRNA (miRNA) precursors which can produce 44
mature miRNAs, many of which are expressed at high levels in
tumors, the same tumors that also express the BARTs (9–11).
Analysis of the residual RNA fragments that remain after excision
of the miRNA hairpins suggests that these miRNAs are removed
from the primary transcript prior to splicing (12). Despite this, the
spliced and polyadenylated mature transcripts persist at high lev-
els in epithelial cells and have been shown to remain in the nucleus
(8, 12). A recent RNA-seq analysis of a panel of EBV-infected
gastric tumors suggested that 99% of all virally derived polyade-
nylated transcripts were BARTs (13, 14).
Infection of the EBV-negative gastric carcinoma cell line AGS
is a useful model for studying EBV epithelial latency since these
cells consistently adopt a highly restricted pattern of expression
that is quite similar to latency I in EBV-positive gastric carcinoma.
Importantly, EBV infection of AGS cells consistently induces an-
chorage-independent growth and increased motility (4, 15, 16).
Gene expression microarray analysis of a single AGS-EBV cell line
compared to parental cells suggested that there are widespread
changes in host transcription due to latent EBV infection and that
the downregulated genes were highly enriched for BART miRNA
targets (4). In the present study, multiple clonal AGS-EBV cell
lines were profiled by RNA-seq, generating data that are more
accurate than data obtained by microarray analysis, that account
for the clonal evolution inherent in any one particular cell line,
and that include an evaluation of not only host but also viral tran-
scription. Pathway analysis identified multiple cellular regulatory
pathways that are consistent with anchorage-independent growth
and transformation. The transcriptional changes predicted activa-
tion of the myc oncogene which would likely be a contributing
factor to the altered growth properties. In addition, RNA-seq
analysis of AGS cells expressing the first full-length cDNA clone of
one of the splice isoforms of the BARTs revealed that the expres-
sion pattern obtained after BART expression overlapped signifi-
cantly with the expression pattern following EBV infection of the
same cells in which the BARTs are expressed at high levels endog-
enously. These data provide the first evidence that the BARTs
function as long noncoding RNAs (lncRNAs) independently of
miRNA formation. Human lncRNAs are quite abundant in the
human genome, with recent evidence from RNA-seq and other
sources suggesting that there are likely nearly as many lncRNA
genes as protein coding genes in the human genome (17). Many of
the functions of these lncRNAs have yet to be determined, al-
though those for which a functional mechanism has been deter-
mined often rely on transcriptional regulation through direct re-
cruitment either of transcription factors or chromatin remodeling
enzymes (18). The transcriptional regulatory functions of the
BARTs, independent of miRNA production, and their abundance
in EBV derived epithelial malignancies suggest that these noncod-
ing RNAs likely contribute to EBV effects on epithelial growth and
transformation.
MATERIALS AND METHODS
Cell lines and culture. The gastric carcinoma cell line AGS was grown in
F-12 media (Life Technologies, Inc.) with 10% fetal bovine serum and
antibiotic/antimycotic (Life Technologies, Inc.). The generation of AGS
cells clonally infected with EBV Akata BX1 was previously described (15).
AGS-EBV cells were also maintained with 500 g of G418 (Life Technol-
ogies, Inc.)/ml to select for retention of the EBV episome. Stable cell lines
expressing pcDNA3-BART were generated by transfection with Lipo-
fectamine 2000 (Life Technologies, Inc.) and selected in media containing
zeocin (Life Technologies, Inc.) at 200 g/ml. Cell lines containing pCEP4
episomal vectors were maintained in 200 g of hygromycin (Roche)/ml to
select for retention of the vector. Normal oral keratinocyte (NOK) and
NOK-Akata cells (a gift from Shannon Kenney, University of Wisconsin)
have been previously described (19) and were maintained in keratinocyte-
SFM (Life Technologies, Inc.) supplemented with epidermal growth fac-
tor, bovine pituitary extract, and antibiotic/antimycotic.
Plasmids and cloning. The myc reporter plasmid pBV-Luc wild-type
(wt) MBS1-4 was a gift from Bert Vogelstein (Addgene, plasmid 16564)
and contains four tandem myc binding sites from the human CDK4 pro-
moter upstream of Firefly luciferase (20). pBV-Luc mut MBS1-4, a gift
from Bert Vogelstein (Addgene, plasmid 16565), which has all four myc
binding sites mutated (20), was used as a negative control. pRL-SV40
(Promega) is a Renilla luciferase-expressing plasmid that was used as a
transfection control. The full 3= untranslated regions (3=UTRs) of poten-
tial miRNA targets were amplified by PCR from genomic AGS DNA using
Phusion Flash High Fidelity PCR mix (Thermo) and cloned into the XhoI/
NotI sites of psicheck2 (Promega). The oligonucleotides used to amplify
each 3=UTR are listed in Table S3 in the supplemental material. In order to
create a full-length BART cDNA clone, a cDNA PCR product from exon 1
to exon 7 (positions 138353 to 160086 on the wt EBV genome
[NC_007605.1]) previously generated from cDNA from a nasopharyn-
geal carcinoma xenograft (12), was extended to the poly(A) site of the
BARTs using overlap PCR with a PCR fragment of exon 7b. The oligonu-
cleotides 5=BARTlong and 3-5exon7b were used to amply the first frag-
ment from the cDNA clone, and the oligonucleotides 3=BARTlong and
5-3exon7b were used to amply the exon7b fragment. After overlap PCR
using these two PCR products and oligonucleotides 5=BARTlong and
3=BARTlong, the resulting PCR product was cloned into the BamHI and
XhoI sites in the multiple cloning site of pcDNA3.1-zeo (Life Technolo-
gies, Inc.). The resulting plasmid was sequenced and confirmed to contain
a full-length BART cDNA that contains exons 1, 1A, 2, 3A, 3B, 4, 5A, 5B,
6, 7A, and 7B (see Fig. 5). In order to move the BART cDNA into the
pCEP4 vector (Life Technologies, Inc.), the entire cDNA was excised from
pcDNA3 by cutting with KpnI/XhoI and inserted into the pCEP4 multiple
cloning site cut with the same enzymes. All restriction enzymes were pur-
chased from NEB and used according to the manufacturer’s instructions.
RNA sequencing. RNA was prepared from cell lines grown for 2 days
to 80% confluence using TRIzol reagent (Life Technologies, Inc.).
Poly(A)-selected, bar-coded, non-strand-specific cDNA libraries were
prepared for sequencing using a TruSeq RNA Sample Prep kit v2 (Illu-
mina) by the UNC Lineberger Genomics Core. Libraries were pooled and
sequenced in pools of six libraries using a HiSeq2000 instrument (Illu-
mina) by the UNC High-Throughput Sequencing Facility. AGS parental,
AGS-EBV, and AGS with pcDNA3 vectors were sequenced using paired-
end 100-bp sequencing, and the pCEP4 cell lines were sequenced using
paired-end 50-bp sequencing. Raw data for all of the sequencing are pub-
licly available at the NCBI short read archive under study SRP060253.
Bioinformatics. RNA sequencing reads were aligned to the human
genome (hg19) and the EBV Akata genome (GenBank accession number
KC207813.1) using the splicing aware read aligner TopHat on the Galaxy
suite. Aligned reads were mapped to specific human Refseq genes using
the Partek Genomics Suite, which was also used to calculate differentially
expressed genes, generate hierarchical clusters, and perform principle
component analysis. In order to visualize the reads representing the BART
cDNA clone, reads that did not map to the human genome using TopHat
were mapped the Akata genome using Bowtie. Aligned reads were visual-
ized using the Integrative Genomics Viewer (21). Enriched molecular
functions and potential upstream regulators for the AGS-EBV data set
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were obtained by running a core analysis on the differentially expressed
genes using Ingenuity Pathway Analysis (IPA) software (Qiagen).
Luciferase assays. Cell lines were grown to confluence in six-well
dishes and transfected with the appropriate vectors using Lipofectamine
3000 (Life Technologies, Inc.). At 48 h posttransfection, the cells were
lysed and assayed using the dual-luciferase report assay system (Promega)
on a Glomax 96 instrument (Promega). For the myc activity assays, 2.7 g
of the pBV-MBS1-4 reporter and 300 ng of the control pRL-SV40 vector
(Promega) were transfected into each well. For the 3=UTR assays, 500 ng
of the indicated psicheck2 vector was transfected into each well.
UPR assay. AGS or AGS-EBV cells were plated into six-well plates at a
density of 106 cells per well 24 h before assay and cultured at 37°C. The
cells were treated with 40 M, 200 M, 1 mM, or 5 mM dithiothreitol
(DTT) for 4 h at 37°C and then harvested for RNA preparation using
TRIzol reagent (Life Technologies, Inc.). An XBP1 splice isoform was
assayed from each RNA sample by using reverse transcription-PCR (RT-
PCR) with a Qiagen Quantifast One-Step RT-PCR system and the primers
5=XBP1 and 3=XBP1 (see Table S1 in the supplemental material). This
PCR generates a 249-bp product from the unspliced RNA and a 223-bp
product from the spliced RNA. PCR fragments were resolved on an aga-
rose gel to distinguish between these two sizes.
Western blotting. Protein lysates were prepared from cells, and West-
ern blot analysis was performed as previously described (22). Primary
antibodies used were mouse -c-myc (Santa Cruz, sc-40) and rabbit
-GAPDH (Santa Cruz, sc-25778).
Quantitative RT-PCR. RNA was prepared from cell lines using TRIzol
reagent (Life Technologies, Inc.). Quantitative RT-PCR was performed
using the Quantifast SYBR green RT-PCR kit (Qiagen) on a QuantStudio
6 Flex real-time PCR system (Applied Biosystems) with primers designed
for each gene tested. In order to detect the BART lncRNA, two sets of
primers were designed: one that spans the exon 4-exon 5 junction (prim-
ers exon4R and exon5aL) and one that spans the exon 6-exon 7 junction
(primers exon6R and exon7aL) (see Table S1 in the supplemental mate-
rial). In both cases, the specific PCR product was only detected in EBV-
positive cells or cells containing the BART cDNA. RNA from specific
cellular fractions was isolated by using a differential lysis technique, fol-
lowed by TRIzol prep, as previously described (12). The percentage of
transcript in the nucleus was calculated from the relative abundance ob-
tained from cycle thresholds using quantitative RT-PCR from an equal
volume of cytoplasmic and nuclear RNA. The primers to amplify specific
human transcripts are listed in Table S1 in the supplemental material and
are identified by the names of the respective genes. These primer pairs
were designed with the help of the NCBI primer blast, and each span an
exon-exon junction of the mature transcript and are predicted to have no
off targets in the human transcriptome. In all cases the reported differen-
tial expression is based on the differences in cycle threshold of control
versus experimental, normalized to the differences in cycle threshold of a
GAPDH reaction used as a control.
RESULTS
EBV effects on cellular expression. In order to better understand
the effects of latent EBV infection in epithelial cells, RNA-seq was
used to obtain a complete transcriptional profile of both unin-
fected and infected AGS cells. mRNA libraries were generated us-
ing the Illumina TruSeq RNA prep kit to obtain libraries from
RNA isolated from three preparations of uninfected AGS cells,
one EBV-infected cell line obtained that has been previously pro-
filed by microarray (4), and two additional EBV-infected AGS cell
lines that have been recently generated (15). Sequence reads gen-
erated by paired-end, 100-bp sequencing on the Illumina HiSeq
2000 instrument were aligned to both the human (hg19) and the
Akata EBV (KC207813) genomes by using the splicing aware read
aligner Tophat. Human alignments were matched to annotated
RefSeq transcripts using the Partek genomics suite software. It was
possible to align the vast majority of reads in this sequencing to the
human genome and most of those reads mapped as pairs to RefSeq
transcripts (Table 1). Consistent with the fact that the infection in
these cells is mostly latent, only a small percentage of the mappable
reads correspond to EBV, ranging from 0.19 to 0.48%. A recent
report examining lytic induction of an EBV-positive Burkitt’s
lymphoma cell line by RNA-seq suggested that lytic cells can pro-
duce ca. 7% of the total sequence reads derived from the virus
(23), which would correspond to a background lytic activation of
around 5% if similar transcription levels occurred in lytic AGS
cells.
It is clear from the analysis of the RNA-seq results that latent
infection with EBV reproducibly alters the transcription pattern
of AGS cells. Principle component analysis revealed that the orig-
inal AGS-EBV cell line obtained from the Hutt-Fletcher lab has a
pattern of transcription that is distinct from the two AGS-EBV cell
lines generated more recently in our lab (Fig. 1A). This likely re-
flects the continuing clonal evolution that occurs in these cell lines
during extended passage. However, hierarchical clustering re-
vealed a large number of consistent changes were common to all
three lines, indicating that latent EBV infection modulates host
cell transcription, and the induced changes can be distinguished
from those that reflect clonal variation between cell lines (Fig. 1B).
After filtering out the lowest expressed transcripts, there were
1,514 genes upregulated and 715 genes downregulated with a P
value of 0.05 (Fig. 1B; see also Table S2 in the supplemental
material). Of these changes, 53 upregulated and 101 downregu-
lated genes were changed 2-fold after EBV infection. The tran-
scriptional changes associated with EBV infection were enriched
in genes with functions related to cell growth and proliferation,
cell death and survival, and gene expression (Fig. 1C). The changes
in expression observed predicted that the infected cells would have
an increase in proliferation and cell viability and a decrease in
apoptosis and cell death, which is consistent with the increased








AGS#1 42,799,160 39,755,541 17,974,295
AGS#2 61,878,112 57,253,646 25,869,971
AGS#3 52,469,526 48,625,673 21,987,733
AGS-EBV#1 49,800,978 45,650,825 20,641,133
AGS-EBV#2 62,470,636 59,981,567 27,159,052
AGS-EBV#3 64,846,600 57,285,114 25,909,124
pcDNA3#1 87,435,366 82,832,788 37,784,366
pcDNA3#2 75,886,016 71,854,311 32,795,626
pcDNA3#3 70,694,780 66,720,313 30,458,784
pcDNA3-BART#1 64,859,972 61,276,130 28,004,326
pcDNA3-BART#2 66,423,548 62,190,749 28,266,128
pcDNA3-BART#3 72,997,746 68,396,572 31,001,562
pCEP4#1 66,755,870 60,509,879 25,812,976
pCEP4#2 70,824,278 67,749,126 29,677,147
pCEP4#3 67,247,644 64,586,394 28,196,855
pCEP4-BART#1 49,707,074 46,745,211 20,092,075
pCEP4-BART#2 77,541,962 72,745,999 31,912,940
pCEP4-BART#3 51,382,276 48,593,505 21,287,109
a That is, the number of read pairs that correctly align together on a known RefSeq
transcript.
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anchorage-independent growth previously observed in these cell
lines (4, 15).
In order to determine whether the transcription changes were
caused by a discrete subset of activators and/or repressors, the
Ingenuity Pathway Analysis (IPA) software package was used to
query possible upstream regulators that could account for these
transcription changes. This analysis suggested that myc, the glu-
cocorticoid receptor (NR3C1), and the insulin receptor were in-
creased in activation and the stress response transcription factor
XBP1, Rb, the inflammatory kinase MAP4K4, and the transcrip-
tion factor p8 (NUPR1) were decreased in activation (Fig. 2A).
These predictions had highly significant P values, reflecting the
degree of overlap with the genes in the data set and significant Z
scores indicative of activation or repression. To confirm activation
of the myc pathway, a luciferase reporter construct containing a
200-bp region of the CDK4 promoter with four myc binding sites
was used to assess myc activity in the parental AGS line, as well as
five independent clonal EBV-infected lines. As a control, the ac-
tivity of the reporter construct with mutations of all four myc
binding sites was also assessed. In four of the five lines tested
(including lines 1 and 2, which were analyzed in the RNA-seq
experiment), the myc activity was higher than in the parental
lines (Fig. 2B). Mutation of the myc sites greatly reduced the
reporter activity. The activation of myc occurred despite a mi-
nor decrease in the transcription of the MYC gene (see Table S2
in the supplemental material) and without a statistically signif-
FIG 1 RNA-seq analysis of AGS cells following EBV infection. (A) Principle component analysis of variation between all expressed transcripts from AGS cells.
The red circles represent three replicate libraries from the AGS parental cells, and the blue circles represent three libraries for independent AGS-EBV cell lines.
The blue circle in the top left of the graph represents the original AGS-EBV cell line obtained from the Hutt-Fletcher lab, and the two blue circles at the bottom
of the graph represent two independently generated clonal EBV-infected cell lines. (B) Hierarchical clustering of genes significantly changed by EBV infection.
The 2,229 genes significantly changed (P  0.05) after EBV infection were clustered independently. Red indicates expression higher than the mean of the six
libraries, and blue indicates expression lower than the mean. (C) IPA software was used to classify genes regulated by EBV infection into categories based on the
known molecular function of the genes. Graphed are categories that were highly enriched in the data sets, with the size of each bar corresponding to the log of
the P value of enrichment. Green bars indicate that the function is predicted to be activated, and red bars indicate that the function is predicted to be inhibited
based on the pattern of expression of these genes. Black bars indicate that the function can be predicted to be neither activated nor inhibited based on the data.
BARTs Encode Both Functional lncRNAs and miRNAs
November 2015 Volume 89 Number 22 jvi.asm.org 11259Journal of Virology
icant increase in c-myc protein levels, as assessed by Western
blotting (Fig. 2C and D).
The IPA method also predicted that XBP1 is significantly in-
hibited despite being expressed at equivalent levels according to
the RNA-seq data. XBP1 is a key regulator of the unfolded protein
response (UPR) and is regulated by a cytoplasmic splicing event
upon endoplasmic reticulum (ER) stress that results in a frame-
shift and the production of a more active transcription factor (24).
To determine whether EBV infection affected the production of
the spliced isoform of XBP1, the RNA-seq reads were examined
across the locus (Fig. 3A). There was no decrease in reads across
the XBP1 alternative splice, suggesting that in both AGS and AGS-
EBV cells XBP1 exists in the unspliced and less active isoform.
However, the RNA-seq analysis indicated that a large number of
the genes activated during the ER stress response are inhibited
following EBV infection. To assess the effects of EBV infection on
the ability of XBP1 to respond to ER stress, AGS or AGS-EBV cells
were treated with increasing amounts of DTT to induce the UPR,
and XBP1 splicing was monitored by RT-PCR. In this assay, EBV
did not affect the ability of XBP1 to be activated in response to ER
stress (Fig. 3B). Taken together, these data suggest that although
many of transcriptional targets of the UPR are downregulated in
response to EBV infection, the mechanism of this downregulation
is not the result of direct effects on XBP1 activation.
Potential effects of EBV miRNAs. AGS cells infected with EBV
express high levels of the BART miRNAs (15), and previous pro-
filing of one AGS line by microarray suggested that a substantial
subset of the downregulated genes after latent infection were di-
rect targets of the BART miRNAs (4). To confirm that the BART
miRNAs contribute to the changes in gene expression profiled in
the multiple infected cell lines in this report, the genes changed in
expression were overlapped with the most extensive lists of BART
miRNA targets published to date, where the BART miRNA targets
were identified by PAR-CLIP in a peripheral effusion lymphoma
cell line dually infected with EBV and KSHV, as well as the NPC
cell line C666 (25, 26). A higher percentage of the downregulated
genes and a lower number of the upregulated genes overlapped
with the PAR-CLIP data sets compared to the null hypothesis,
which would be the percentage of all genes expressed in AGS cells
(based on the RNA-seq data) that overlap the PAR-CLIP data set
(Fig. 4A and B). The decrease in expression is in accordance with
expected effects of miRNAs. To determine whether some of the
downregulated genes were direct targets of miRNAs, the 3=UTRs































































































FIG 2 Latent infection of AGS cells with EBV induces myc transcriptional activity. (A) IPA software was used to predict upstream regulators of the significantly
changed genes. The P value of overlap is a measure of how likely the overlap between genes in the data set, and genes targeted by the upstream regulator occurred
at random. The activation Z score is an indication of whether the upstream regulator is activated or repressed based on the changes observed in the data set. The
higher the absolute value of the Z score, the more likely the upstream regulator is affected, with positive Z scores indicating activation and negative Z scores
indicating inhibition. The list shown is the most significant upstream regulators based on P value that have a Z score of 2, which is a cutoff for statistical
significance. (B) AGS cells and five clonal AGS-EBV lines were transfected with a reporter with the four myc binding sites from the CDK4 promoter driving Firefly
luciferase (wt) or a control reporter in which all four sites have been mutated (mut). A plasmid expressing Renilla luciferase was used as a transfection control.
After 48 h, the cells were assessed for each luciferase activity, and the ratio of firefly/Renilla luciferase for the wt reporter in the parental AGS cells was set to 1. The
assay was performed six times for the wt reporter and three times for the mutant reporter, and the graph represents the mean value, with error bars indicating the
standard errors of the mean (SEM). (C) Western blot showing the levels of c-myc protein in each of the cell lines in panel B with GAPDH levels assessed as a
loading control. (D) The average result of four independent c-myc Westerns normalized to GAPDH is plotted as the expression relative to the AGS control cells.
Although there is a trend toward an increase in c-myc levels, none of these are statistically significant based on a one-sample t test. The asterisk represents a t test
result of P  0.10.
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Given that the PAR-CLIP data set is derived from a very distinct
cellular context and in order to potentially identify novel miRNA
targets, a miRNA target prediction program (PITA) was also used
to query the 3=UTRs from each downregulated gene against the
top 15 BART miRNAs in terms of expression for predicted
miRNA sites. From the resulting list of potential targets, the UTRs
for nine genes (MXI1, GSTM, RASA1, CTNNA1, GPX2, DUSP6,
PTPN6, JMY, and IER3) were cloned. CTNNA1, JMY, and IER3
were also identified as BART miRNA targets in the BC1 PAR-CLIP
data set. These genes all have potential tumor suppressive func-
tions, and thus downregulation might contribute to the increased
transformation phenotype of these cells (Table 2). Of these nine
selected genes, the 3=UTRs of eight of the genes, with the exception
of RASA1, had significantly decreased activity in EBV-infected
cells, although the results of IER3 fell just short of statistical sig-
nificance (Fig. 4C). These data indicate that the BART miRNAs
are likely responsible for some of the gene expression changes in
the EBV-infected AGS cells. Interestingly, MXI1 is a negative reg-
ulator of myc, which may partially explain the activation of myc
following EBV infection.
The spliced EBV BART RNA modulates cellular expression.
Previous work has shown that the most abundant polyadenylated
viral RNAs in EBV-positive gastric carcinoma samples are the
spliced BART transcripts (13), which are also expressed at high
levels in the AGS-EBV cells. Considerable evidence exists to sug-
gest that the BARTs do not encode proteins (27), and previous
studies have suggested that these transcripts are not exported to
the cytoplasm (8, 12). However, these spliced transcripts from
which the primary miRNA sequences contained within the in-
trons are removed are quite abundant and stably remain in the
nucleus. These properties suggest that the BARTs possibly func-
tion as noncoding RNAs in the nucleus, analogous to human
lncRNAs. In order to determine whether the BART RNAs have a
role independent of generation of miRNAs, a full-length cDNA
clone was generated by overlap PCR from the longest BART
cDNA successfully cloned from the C15 nasopharyngeal carci-
noma xenograft (Fig. 5A and B) (12). This cDNA was repaired to
include the 3= sequences of exon 7 and the polyadenylation site
using Akata DNA. This full-length 2-kb cDNA corresponding to
one possible isoform of the BARTs was cloned into the mamma-
lian expression plasmid pcDNA3 and the EBNA1 based episomal
vector pCEP4 (Fig. 5A and B). Cell lines were generated by select-
ing for three independent stable integrations of the pcDNA3 vec-
tors or three independent lines maintaining the episomal pCEP4-
BART in AGS cells. Quantitative RT-PCR for the splices between
exons 4-5 and exons 6-7a was used to determine the relative ex-
pression of the BART cDNA. The pcDNA3 lines expressed the
BART cDNA to levels comparable to EBV-infected cells (Fig. 5C),
while the pCEP4 lines expressed higher levels than the EBV-in-
fected cells (Fig. 5D). Endogenous BART RNAs remain in the
nucleus; therefore, the localization of the expressed cDNA clones
was determined by nuclear fractionation of cells, followed by RNA
preparation and quantitative RT-PCR. Importantly, a majority of
the expressed RNA remained in the nucleus at levels comparable
to the nuclear U5 RNA (Fig. 5E).
In order to determine the relative abundance of this particular
BART isoform cloned from the cDNA in the AGS-EBV cells, the
RNA-seq data aligned to the viral genome were analyzed for
spliced reads. Because these data were generated from sequencing
that cannot distinguish between strands, it is not possible to sep-
arate reads that derived from the BART region from reads that
represent the lytic transcripts on the opposite strand from the
BARTs. However, by tallying the number of reads that span the
various splice junctions possible among the BARTs, it is possible
to determine the abundance of various splice isoforms of the tran-
scripts. In AGS cells there is a large variety of splicing events that
occur at the 5= end of the transcripts, but starting with exon 3,
direct splicing of exon 3-4-5-6-7 appears to be by far the most
abundant splice isoform (Fig. 6A). The alternative splicing events
within exons 3, 5, and 7 that have been previously described (6)
were also detected, although at a much lower abundance (Fig. 6A).
These data are in good agreement with the previously published
splicing analyses performed using EBV gastric carcinoma tumors
and EBV-infected lymphocytes, suggesting that the splicing pat-
tern of the BARTs is relatively constant during EBV latency (13,
28). These data suggest that the cDNA clone that was generated












FIG 3 Regulation of XBP1 during EBV infection of AGS cells. (A) Graphical
representation of the numbers of reads aligned across the XBP1 locus from
AGS and AGS-EBV cells. At the top is an illustration of the structure of the
XBP1 transcripts, in which the first exon is on the right. The XBP1(S) isoform
results from a cytoplasmic removal of 26 nucleotides from the fourth exon, as
indicated. The number of reads spanning each nucleotide is represented by the
height of the bar in the histogram, and the shading of the bar represents the
nucleotide identity. The lower histogram is zoomed in on just exon 4 showing
reads spanning the internal splice. (B) AGS or AGS-EBV cells were treated with
40 M, 200 M, 1 mM, or 5 mM DTT for 4 h. Cells were then harvested, and
the XBP1 splice isoform status was assessed by RT-PCR. The predicted sizes for
XBP1(U) and XBP1(S) are indicated.
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it is not the most abundant isoform. In order to predict what effect
alternative splicing might have on the structure and thus the func-
tion of the BART RNAs, the RNAfold webserver was used to gen-
erate predicted structures for both the BART cDNA cloned for this
study and the larger splice isoform that is most abundant based on
RNA-seq and lacks the additional splicing within exons 3, 5, and 7
(Fig. 6B). The predicted structures suggest that the downstream
splicing events in exons 3, 5, and 7 do not have major effects on the
structure of the 5= region of the RNA, suggesting that common
functions for multiple splice isoforms may be possible. However,
the additional sequences in the unspliced exons does dramatically
change the base pairing in the 3= region of the molecule, suggest-
ing that each splice isoform might have unique functions depen-
dent on the distinct secondary structure.
As a first attempt to understand whether the BART RNAs have
a function in addition to being the template for miRNA produc-
tion, the six independently derived cell lines containing the BART
cDNA clone were subjected to RNA-seq, along with six empty
vector control cell lines created in parallel. The use of six indepen-
dently derived cell lines and six controls allows for considerable
statistical power and enables the identification of changes due to
the actual expression of the BART cDNA and not resulting from
clonal variation. The sequencing was performed and analyzed
identically to the EBV-infected cells, with the exception that the
sequencing was 50-bp pair-end reads. The depth of coverage and
percentage of reads aligning to the human reference genome were
very similar to the previous sequencing (Table 1). In order to
confirm expression of the full-length BART cDNA, the reads were
also aligned to the Akata genome. The BART reads span the length
of the clone as expected (see Fig. S1 in the supplemental material).
Analysis of the differential expression of genes between these
libraries indicated that the major factor influencing expression
was the type of expression vector used, and the expression of the




























































































FIG 4 BART miRNAs contribute to the downregulation of cellular gene expression. (A) Bar graph showing the percentages of genes that overlap between the
genes increased (Up), decreased (Down), or not changed after EBV infection and an experimentally determined set of BART miRNAs targets from BC1 cells. The
overlapped observed is graphed in black, and the overlap expected if the BART miRNAs did not contribute to gene changes in graphed in white. This null
hypothesis expectation is the fraction of genes expressed in AGS cells (n  11,476) that also appear in the BART target data set (n  2,364), which is 20.6%. (B)
The same analysis performed from a BART miRNA target set from C666 cells. In this instance, there were 866 targets expressed in AGS cells, and thus the null
hypothesis is 7.6%. (C) A 3=UTR luciferase reporter assay was performed. The entire 3=UTR for each of the indicated genes was cloned onto the coding sequence
of Renilla luciferase in the psicheck2 vector, which also contains the firefly luciferase gene expressed as a separate transcript. Each resulting vector was transfected
into AGS and AGS-EBV cells, and the activity of Renilla/firefly luciferase was measured at 48 h posttransfection. Plotted is the mean of three independent
transfections, normalized to the ratio obtained from an empty vector in each cell line. The error bar represents the SEM. The asterisks refer to the results of a
Student t test between the AGS and AGS-EBV samples (*, P  0.05; **, P  0.01; ***, P  0.001). The IER3 assay had a P value of 0.055.
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ever, one pair of pCEP4 control and BART libraries was signifi-
cantly different from all of the others (Fig. 7A). For subsequent
analysis, these outliers were excluded, and the five remaining
BART expressing cell lines were compared to the corresponding
controls. Principle component analysis indicated that PC1 repre-
senting 46.2% of the variation between these 10 libraries was ac-
counted for by the difference between the integrating and epi-
somal vectors; however, PC2 representing 23.3% of the variation
was directly due to BART cDNA expression (Fig. 7B). The large
differences between the integrating versus episomal vectors is













MXI1 –1.19 BART 22-3p (7), BART19-3p (10) 0.81 Negative regulator of myc
GSTM –1.21 BART10-3p (2) 0.73 Detoxification of carcinogens
RASA1 –1.07 BART10-3p (2) 1.94 Negative regulator of ras
CTNNA1 –1.22 BART12-3p (34) BART5-5p (4) 0.78 Inherited mutation leads to gastric cancer
GPX2 –3.12 BART17-5p (8) 0.74 Prevents inflammation dependent
tumors in gastric epithelium
DUSP6 –1.20 BART11-3p (9) 0.64 Negative regulator of ERK, activated by
p53
PTPN6 –1.11 BART6-3p (6) 0.76 Negative regulator of tyrosine kinase
signaling
JMY –1.31 BART9-5p (5), BART19-3p (7),
BART17-5p (8), BART11-3p
(9), BART2-5p (17)
BART10-3p (2), BART5-5p (4),
BART17-5p (8), BART18-3p
(10), BART19-3p (13)
0.68 Coactivator of p53, helps integrate actin
dynamics and adherens junctions to
p53 function
IER3 –1.45 BART17-3p (14) BART2-3p (42) 0.89 Stress-inducible gene that can
downregulated NF	B, ERK, and Akt
a Numbers in parentheses represent the rank in terms of BART miRNA abundance in AGS-EBV cells according to previously published miRNA sequencing data (15).
b PAR-CLIP predicted BART targets, as determined previously (23).
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FIG 5 Expression of a Full Length BART cDNA. (A) Diagram of the BART locus. (B) Exon structure of the BART cDNA cloned into pcDNA3 and pCEP4 vector.
(C) Expression of the BART cDNA clone in three independently derived, pcDNA3-based, stable AGS cell lines. Expression is measured by quantitative RT-PCR
using primers that span the exon 4-5 or exon 6-7 junctions and is expressed relative the same PCR performed from AGS-EBV cells. (D) Expression of the BART
cDNA from three independently selected cultures of AGS cells containing the episomal pCEP4-BART vectors. PCR was performed as described for panel C. (E)
Nuclear fractionation of pcDNA3 stable lines to determine the localization of the expressed BART. Cells were fractionated into nuclei and cytoplasm, and RNA
was prepared from both samples and subjected to quantitative RT-PCR using the same primers as in panels C and D, as well as primers recognizing GAPDH
mRNA and the nuclear RNA U5 as controls. The results are expressed as the percentage of the PCR product derived from each of the fraction. As a control,
AGS-EBV cells were also fractionated and show the expected localization of the BARTs and U5 in the nucleus and GAPDH mRNA in the cytoplasm.
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likely due to multiple changes in the transcriptional profile that
occur during selection of stable lines, as well as the fact the pCEP4
vectors also express EBNA1, which likely also mediates some ef-
fects on cellular transcription. However, the use of multiple cell
lines for each type of vector allows us to isolate the consistent
changes are solely dependent upon BART expression.
Analysis of both the integrating and the episomal cell lines
revealed that the BART cDNA was responsible for a considerable
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FIG 6 Splicing pattern of the BARTs obtained from RNA-seq. (A) Diagram of the BARTs drawn to scale, with boxes indicating exons and a connecting line
indicating introns. The positions of the BART miRNAs are indicated by red vertical lines. Dotted lines within the exon boxes indicate alternative splicing events.
Indicated below are the number of reads that span exon-exon junctions in each of the three libraries of AGS-EBV cells. These data suggest that the most common
splicing pattern for the BARTs includes exons 1, 2, 3, 4, 5, 6, and 7 without the alternative splicing events that occur within exons 3, 5, and 7. It also suggests that
there is much greater variation in the splicing pattern near the N terminus of the transcripts. Only splicing events that occurred at least five times across the three
libraries are illustrated. (B) The RNAfold Webserver was used to generate minimum free energy predicted structures for the RNA encoded by the BART cDNA
cloned in this study (left) and a BART RNA without alternative splicing in exons 3, 5, and 7 (right). Nucleotides are color coded by exon as indicated in order to
better visualize from which part of the RNA the particular secondary structures are derived.
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number of consistent transcriptional changes (Fig. 7C). In total,
there were 2,405 genes upregulated and 1,999 genes downregu-
lated with a P value of 0.05 (see Table S3 in the supplemental
material). Of those, 96 genes were upregulated, and 240 genes
were downregulated 2-fold. Importantly, many of the genes reg-
ulated by the BART were also identified as genes regulated follow-
ing EBV infection (Fig. 7D and E). Perhaps most striking is the fact
that nearly 50% of the genes downregulated 2-fold after latent
EBV infection were also downregulated in the BART data set with
the majority of the changes at least 2-fold (Fig. 7E). In addition, by
plotting the changes in expression in the AGS-EBV cells against
the changes in expression due to BART expression, a strong pos-
itive correlation can be observed (Fig. 7F). Taken together, these
data suggest that a subset of the changes in gene expression in-
duced by latent EBV infection in AGS cells is due to the expression
of the BART nuclear RNAs and suggests that the spliced BART
transcripts function as lncRNAs and from this point onward are
referred to as the BART lncRNA.
Given the large overlap between the genes downregulated by
EBV infection and BART lncRNA expression, the function of the
BART lncRNA in downregulating specific cellular genes was con-
firmed by qRT-PCR in six AGS-EBV cell lines (three of which had
been profiled by RNA-seq, and three of which were not), as well as
three independent sets of pCEP4 and pCEP4-BART lines that
were not part of the RNA-seq data. Primers were designed for
eight genes of interest that were strongly downregulated in both
the AGS-EBV, as well as the BART RNA-seq data sets, and that
would possibly contribute to the altered growth properties and
IPA predicted pathways. These genes include PGC, a secreted gas-
tric protease shown to be a tumor suppressor in the context of
gastric cancer. The proapoptotic gene RNF144B and the angio-
genesis factor VEGFA were analyzed in addition to genes involved
FIG 7 RNA-seq analysis of BART expressing cell lines. (A) Principle component analysis of variation between expressed transcripts from the six BART
containing cell line transcription profiles, as well as the six vector control cell lines. Diamonds indicate pcDNA3 integrated stable cell lines, and squares indicate
pCEP4 episomal vector lines. BART expressing libraries are shown in red, and the vector controls are shown in blue. The squares at the bottom of the graph are
the first set of pCEP4 lines (pCEP4#1 and pCEP4-BART#1) and were excluded from further analysis as outliers. (B) Principle component analysis was repeated,
excluding the two outliers indicated in panel A. Principle component 1 (x axis) separates the samples based on integrating versus episomal vector, and principle
component 2 (y axis) separates the samples based on BART expression. (C) Hierarchical clustering of genes significantly changed by BART expression. The 4,404
genes significantly changed (P  0.05) following BART expression were clustered independently. Red indicates expression higher than the mean of the 10
libraries, and blue indicates expression lower than the mean. Clustering of the samples first separates the pcDNA3 samples from the pCEP4 samples and then the
BART expression from the vector controls. (D) Overlap between the AGS-EBV changed genes and the BART changed genes. For the genes upregulated and
downregulated in the AGS-EBV data set, the number of genes changed in the same direction 2-fold and 2-fold in the BART data set are indicated. (E) Analysis
similar to that depicted in panel D, but only considering genes that changed 2-fold in the AGS-EBV cells. (F) Correlation between the AGS-EBV and BART data
sets. For each gene that was significantly changed in both data sets, the mean ratio is plotted for the AGS-EBV cells on the x axis and the BART cells on the y axis.
A linear trendline is shown that indicates the positive correlation between these two data sets with the associated R2 value for the line.
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in the unfolded protein response (ATF5 and SLC7A11) and cell
adhesion and migration (RASIP1, CDH11, VEGFA, and ITGA6).
The expression of all eight of these genes was greatly decreased in
the independently derived pCEP4-BART lines, suggesting that
these results are highly reproducible (Fig. 8A). In addition, several
of these genes were also significantly decreased across all of the
AGS-EBV cell lines analyzed by RT-PCR, further suggesting a
common mechanism of function for the BART lncRNAs in AGS
cells (Fig. 8B). To determine whether these same genes were af-
fected by EBV in another epithelial cell line, normal oral keratino-
cytes (NOKs) infected with EBV-Akata were analyzed. All eight of
these genes were also downregulated in NOKs following EBV in-
fection (Fig. 8C). Many of these genes, including RASIP1,
SLC7A11, CDN11, and ITGA6, were also downregulated in the
EBV-infected NPC cell line C666 that expresses high levels of the
BARTs compared to an EBV-negative NPC cell line (29).
DISCUSSION
Despite the high prevalence of gastric cancer throughout the
world and the clear association of latent EBV infection in a sub-
stantial subset of this tumor, relatively little research has addressed
the mechanism through which the greatly restricted viral expres-
sion that is characteristic of this tumor promotes tumor forma-
tion. One of the biggest obstacles in studying EBV-positive gastric
carcinomas is the lack of readily available EBV-positive gastric
carcinoma cell lines and appropriate control cells for comparison.
In the present study, infection of an EBV-negative gastric carci-
noma cell line in vitro was used to address the specific contribu-
tions of latent viral infection to transformation. This model has
the advantage of adopting the same restricted type I latency pat-
tern as EBV-positive tumors, which is characterized by very lim-
ited protein expression (4). Analysis of the transcriptional changes
induced by EBV infection of AGS cells predicted increased cellular
proliferation and decreased apoptosis, which are consistent with
anchorage-independent transformation. We provide here evi-
dence that at least two classes of noncoding RNAs, the BART
miRNAs and the spliced and polyadenylated BART nuclear RNAs
derived from the same primary transcripts from the BamHI A
region of the viral genome, both contribute to the reprogramming
of the host cell gene expression. Importantly, the data presented
are the first evidence that the BART spliced RNAs are functional,
despite not being translated, presumably through mechanisms
analogous to human lncRNAs.
An additional important finding of this sequencing study was
identification of myc activation during EBV latency in AGS cells.
This was first predicted by an analysis of the transcriptional
changes and then confirmed using a myc-responsive luciferase
promoter. EBV type I latency is characteristic of Burkitt lym-
phoma, where myc is activated through translocation (30). In type
III latency, EBNA2 is known to directly activate c-myc through
transcriptional activation (31). In contrast, in AGS cell latency,
EBNA2 protein is not expressed (4), and transcriptional activation
of c-myc was not detected by RNA-seq. Considering that the ex-
pression of the BART miRNAs is considerably higher in gastric
cancer than in BL and thus presumably so is the BART lncRNA
(32), this potentially indirect mechanism of activation may be
specifically relevant in epithelial cells which have high levels of the
BARTs. Interestingly, one of the downregulated genes that re-
sponded in the 3=UTR assay was the negative regulator of myc,
MXI1. Thus, effects on MXI1 may be at least partially responsible
for this increase in myc activity. In addition, EBV infection in AGS
cells has been shown to decrease expression of the let-7 family of
miRNAs (15) which directly regulate myc translation (33, 34).
However, the myc protein levels were not consistently affected in
the AGS-EBV cell lines, suggesting that the effect of decreased let-7
miRNA is unlikely to be the sole explanation for the increase in
myc activity. It is likely that multiple factors contribute to this
important phenotype of myc activation.
Expression of the BARTs represents the vast majority of poly-
adenylated viral transcription in gastric cancer (13, 14), and a
correlated high expression of the BART miRNAs was also ob-




















































































FIG 8 Confirmation of BART lncRNA downregulation of cellular genes by
RT-PCR. (A) Quantitative RT-PCR was performed from RNA harvested from
pCEP4 or pCEP4-BART AGS cell lines on the indicated genes. Assays were
performed on three independent sets of cell lines, and expression was normal-
ized first to a GAPDH control, and the mean result from pCEP4 for each gene
was set to 1. The error bars represent the SEM. The asterisks refer to the results
of a Student t test between the pCEP4 and pCEP4-BART samples (**, P  0.05;
***, P  0.01). (B) Quantitative RT-PCR was performed as for panel A from
AGS cells and six independent AGS-EBV cell lines. Graphed is the mean result
from two RNA preps from AGS cells, as well as each of the AGS-EBV cell lines
with the error bars and a Student t test as in panel A. (C) Quantitative RT-PCR
was performed as in panel A from NOK and NOK-EBV cells.
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define the role of the BART miRNAs in the transformation ability
of the virus. A naturally occurring deletion variant of EBV, B95-8,
lacks most of the BART region (36) and a recombinant EBV lack-
ing all viral miRNAs are still able to transform primary B lympho-
cytes in vitro, suggesting the BART miRNAs are not required for
transformation of B cells (37). However, a recent study has sug-
gested that expression of the BART miRNAs alone in AGS cells can
promote tumor growth when the cells are passaged in mice, sug-
gesting these miRNAs have transforming properties in epithelial
cells in vivo (38). Evidence in the present study suggests that the
ability of latent EBV infection to alter the growth of AGS cells also
likely reflects expression of the BART miRNAs as the downregu-
lated transcripts observed by RNA-seq are enriched in predicted
BART miRNA targets. Several of these genes are important tumor
suppressors, and the data presented here reveals that eight such
genes are regulated at the level of the 3=UTR by EBV infection,
strongly implying a role for the BART miRNAs. However, RNA-
seq analysis revealed that the BART lncRNA also had a significant
effect in the transcriptional reprogramming associated with latent
EBV infection in these cells. Cloning and expression of the first
full-length cDNA clone of a BART induced expression changes
that largely mimicked a subset of the changes that occurred during
EBV latent infection. This is particularly impressive considering
that the cDNA expressed represents only one of multiple splice
isoforms present during latent infection. Future studies will po-
tentially delineate distinct functions for the other splice isoforms
of the BART lncRNAs. Interestingly, the one tumor suppressor
that did not respond in the 3=UTR assay, RASA1, was downregu-
lated in response to BART lncRNA expression, suggesting that it is
the lncRNA and not the miRNAs that is responsible for regulation
of this gene. RASA1 is likely to be particularly important as it is a
negative regulator of the ras oncogene. Interestingly, RASA1 mu-
tations have been shown to be prevalent in EBV-negative gastric
cancers (14).
The RNA-seq analysis presented here suggests that EBV infec-
tion and the BART lncRNAs regulate genes involved in the un-
folded protein response (UPR). IPA of the AGS-EBV RNA-seq
data suggested that XBP1 may be downregulated since many of the
targets of XBP1 are decreased following EBV infection. XBP1 is
one of three master regulatory transcription factors that make up
the UPR, along with ATF4 and ATF6 (24). Additionally, XBP1
also functions in adaptive immunity since it is required for plasma
cell differentiation (39). EBV reactivation that occurs upon
plasma cell differentiation is regulated by XBP1, which can acti-
vate the promoter of the immediate-early gene, BZLF1 (40). This
leads to the interesting hypothesis that in EBV epithelial latency
the virus is suppressing XBP1 activity in order to remain latent.
However, the level of XBP1 was unchanged in the RNA-seq data
set and analysis of the splicing pattern indicated that the expressed
XBP1 is the unspliced and thus less active splice variant. In addi-
tion, induction of ER stress in the AGS cells resulted in activation
of XBP1 and the switch to the spliced variant, which occurred
equally in both uninfected and infected cells. Thus, the predicted
inhibition of the UPR was not due to effects on XBP1. However, in
both the AGS-EBV and BART expressing AGS cells, both ATF5
and ATF6 had decreased expression. ATF6 is one of the three key
transcription factors known to activate transcription in response
to ER stress and ATF5 is another stress response transcription
factor that responds to amino acid limitation through a mecha-
nism analogous to ATF4 (41). Potential direct or indirect effects
on these key regulators of the UPR by the BART lncRNAs are likely
responsible for the subsequent decrease observed in stress respon-
sive genes in the AGS-EBV cells.
Human lncRNAs have been shown to have a diverse array of
functions. Nuclear lncRNAs often regulate transcription through
directing epigenetic modifications to distinct regions of the chro-
matin (18). Additional studies will be required to understand the
mechanism by which the BART lncRNAs modulate expression to
downregulate a distinct subset of genes during EBV epithelial la-
tency. Perhaps the mostly widely recognized strategy used by
lncRNAs for the silencing of genes is disposition of the H3K27me3
mark through the recruitment of the polycomb repressive com-
plex 2 (PRC2) (42). Alternatively, one prominent feature well es-
tablished for EBV-positive gastric carcinomas is an extremely high
level of CpG island promoter methylation that also results in the
silencing of many important genes (14, 43, 44). It is tempting to
speculate that the BART lncRNAs may affect histone regulation or
potentially contribute to directing the DNA methylation pheno-
type. Many other mechanisms of transcriptional regulation are
possible, and several have been ascribed to lncRNAs. The contin-
ued study of the function of these viral transcripts will likely yield
new insights into the role of EBV in promoting growth and trans-
formation of epithelial cells and also to the potential functions of
lncRNAs.
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